DysFUNctional Pain 5/19/2016. Potential conflicts of interest. Objectives
|
|
- Garry Simmons
- 5 years ago
- Views:
Transcription
1 DysFUNctional Pain CHRIS COOK PHARM.D. Potential conflicts of interest Nothing to disclose Objectives Understand the pathophysiology of neuropathic pain and fibromyalgia Explain multimodal therapy in regards to the treatment of pain Explain the mechanism of action of the types of medications used to treat neuropathic pain and fibromyalgia Be able to determine best fit medications for patient cases based on MOA, side effects, interactions etc. 1
2 Classifications of Pain Type of Pain Acute Post-operative Trauma Chronic Cancer Non-Cancer Source of pain Nociceptive Neuropathic Physiology of Nociception Transduction Transmission Perception Modulation 2
3 Transduction Ion Transfer K + = Potassium Na + = Sodium Ca ++ = Calcium Generate an action potential Inflammatory Soup Transmission Aδ Nerve fibers Large Heavily myelinated Sharp well localized pain C-Afferent fibers Smaller Less myelination Dull-Aching poorly localized pain Transmission 3
4 Perception End result of the neural activity of pain transmission Conscious awareness of pain Requires activation of the higher brain structure Thalamus Limbic System Generate a network of cortical and subcortical gray matter Includes processes that influence movement, emotions, and drives (related to pain) Modulation Neurotransmitters Endogenous Opiates Enkephalins Endorphins Dynorphins Nociceptins (ORL-1) NE/DA/5HT 3 GABA Neurotensin Receptors µ = Mu Mu 1 = desired effects Mu 2 = undesirable effects ĸ = Kappa Desirable and undesirable effects δ = Delta & ơ = Sigma NMDA antagonism 4
5 Definition of Neuropathic Pain Abnormal processing of sensory input by the peripheral or central nervous system Peripheral Mechanisms of Neuropathic Pain Collateral sprouting (also in CNS) Peripheral sensitization by release of substances from damaged cells Alteration in ion channel expression Recruitment of silent nociceptors Lowered threshold for nerve depolarization Central Mechanisms of Neuropathic Pain Prolonged binding of neurotransmitters glutamate & substance P hyperexcitability of central neurons Lowered threshold for nerve conduction Increased response to stimuli (allodynia, hyperalgesia) Enlarged receptor field NMDA receptor activation influx of Ca ++ 5
6 IASP NeuPSIG 1 st line = TCA s, SNRI s, Ca ++ channel α 2 -δ ligand TCA s 1 st line unless significant cardiac history Duloxetine 1 st line for Peripheral Diabetic Neuropathy Lidocaine topical for patients with well localized pain Presentation with severe pain should begin with opioids IASP NeuPSIG 2 nd line = Tramadol Opioid combinations w/apap 3 rd line = Miscellaneous agents Antidepressants not previously mentioned SSRIs (bupropion, citalopram, paroxetine) Carbamazepine for Trigeminal Neuralgia Multimodal Analgesia Using 2 or more classes of medications to treat a painful condition Used to target different pain mechanisms in the PNS and CNS Allows for equal or greater analgesia Lower doses of each agent (in general) Decreased side effects Increased efficacy 6
7 Neuropathic Pain Syndromes Painful Polyneuropathy (PPN) Postherpetic Neuralgia (PHN) Trigeminal Neuralgia (TN) Central Neuropathic Pain (CP) Other Neuropathic Pain Conditions (NP) Painful diabetic neuropathy (PDN) Painful Polyneuropathy 1 st line = Gabapentin/pregabalin, TCA s, SNRI (duloxetine, venlafaxine) 2 nd line = Tramadol, acetaminophen, combined 3 rd line = Strong opioids HIV associated polyneuropathy Lamotrigine (if on antiretrovirals), smoking cannabis, capsaicin Postherpetic Neuralgia 1 st line = TCA, gabapentin/pregabalin, lidocaine 2 nd line = Capsaicin, strong opioids 7
8 Trigeminal Neuralgia Oxcarbazepine, carbamazepine Patients with intolerable side effects from 1 st line therapy Lamotrigine Surgery Central Neuropathic Pain 1 st line = Gabapentin/pregabalin, amitriptyline 2 nd line = Tramadol, strong opioids Lamotrigine Post stroke pain Spinal cord injury with incomplete cord lesion Allodynia Cannabinoids in patients with multiple sclerosis Pain score from a patient point of view ktop_uri=%2fwatch%3fv%3dcp4zgb9h3cg 8
9 Tricyclic Antidepressants Mechanism of Action 5HT 3, NE reuptake inhibitor Anticholinergic-antimuscarinic α1-adrenergic antagonist Antihistamine (H1), Sodium channels inhibition at overdose levels Selective TCA s = imipramine, nortriptyline, amitriptyline Less anticholinergic side effects TCA s Continued Dosing: Start with single low dosages at bedtime titrated as tolerated. Effective doses vary. TCA s have much better efficacy than the SSRI s Tertiary amines are more effective than secondary amines but with a worse side effect profile Tertiary Amitriptylline, imipramine Secondary Desipramine, nortriptyline Pain relief properties are not related to antidepressant properties Common Side Effects of TCA 9
10 SNRI (duloxetine, venlafaxine) Mechanism of Action Side Effects Inhibits the reuptake of serotonin and norepinephrine back into the presynaptic neuron in the descending inhibitory neuropathway GI disturbance, somnolence hyperhidrosis, dizziness (w/discontinuation), rare elevations in plasma glucose and hepatic enzymes HTN Best tolerated = venlafaxine ER>IR>duloxetine Polling Question What is the mechanism of action of gabapentin? A. Binds to the GABA site of GABAergic neurons in the CNS causing inhibitory firing of pain signals in the descending pathway B. Binds to the GABA site of GABAergic neurons in the CNS causing inhibitory firing of pain signals in the ascending pathway C. Binds to voltage gated Ca ++ channel α 2 -δ modulating the release of excitatory neurotransmitters D. Bind BZD receptor on GABAergic neurons causing membrane stabilization and decreased action potential Ca ++ Channel α 2 -δ Ligand MOA: Binds to voltage gated Ca ++ channel α 2 -δ, this is a presynaptic channel that modulates the release of excitatory neurotransmitters which participate in nociception 10
11 Gabapentin Non-linear kinetics 2 saturable absorption F of gabapentin is inversely proportional to the dose secondary to the L-amino transport system Absorption is greatly increased by food t½ increases from average of 6 hours to up to 40 hours in patients with decreased renal function Dosing in neuropathy requires usually 1800mg/day Titration may occur at increases of ~300mg/day Pregabalin In addition to the MOA mentioned above may affect descending serotonergic/noradrenergic pain pathway from brainstem to spinal cord Side Effects >10% Pregabalin Peripheral edema, weight gain Somnolence & dizziness up to >35% Xerostomia, constipation Tremor Gabapentin Ataxia, dizziness, somnolence 11
12 Lamotrigine Mechanism of action Inhibition of the release of glutamate and voltage gated Na + channels Side effects Extra emphasis on serious skin reaction, GI side effects and vision changes Kinetics 98% bioavailable, t½ =24-48hr, All neuropathic and fibromyalgia are off label uses Carbamazepine Mechanism of action Thought to work in the thalamus and possibly affect sodium channels similar to lamotrigine. Side effects Constipation Vomiting Dizziness Capsaicin Mechanism of action Induces the release of substance P until depleted relief until substance P is repleted by the body Side effects Pain Pain Pain Discontinuation rate due to worsening of pain levels 12
13 Lidocaine MOA: Blocks initiation and conduction of nerve impulses Dosing up to 4 patches at a time (mfr = 3) 11hr to peak concentration 1-2 hr. t½ 13
14 Opioids for chronic pain NIH Short-term studies show equivocal evidence reducing neuropathic pain Intermediate-term studies demonstrate significant efficacy of opioids over placebo Reported adverse events of opioids are common but not life threatening Opioids MOA: Opioid receptor agonist decreasing pain impulse transmission at the spinal cord level and higher in the CNS. Also causes peripheral vasodilation by depressing the responsiveness of alpha-adrenergic receptors. Binding to opiate receptors in the periphery causes smooth muscle relaxation 14
15 15
16 Opiate Effects (CNS) Analgesia Direct stimulation of the chemoreceptor trigger zone (CTZ) Decreased responsiveness in respiratory center Opioid effects (periphery) Decreased propulsive contractions of the GI tract Decreased biliary and pancreatic secretions Histamine release causing pruritus Venous vasodilation Opioid Fun Facts Anecdotal case report: 63yo M s/p bowel resection for colorectal cancer receiving Morphine sulfate extended release (GENERIC) Hydromorphone Longer respiratory depressive effect than analgesic effect Lipophilicity Morphine Oxycodone Hydromorphone Methadone Fentanyl 16
17 Tramadol MOA: Tramadol and its metabolite (M1) are centrally acting mu receptor agonists, also inhibits reuptake of serotonin and norepinephrine Onset = 1hr, Duration = 9hr, t½ = ~7hr tramadol, ~8hr M1, Side Effects: Constipation, nausea, pruritus, sedation, dizziness, headache Methadone MOA Synthetic mu opiate receptor agonist Antagonism of NMDA receptor Reuptake inhibitor of 5HT 3 and NE Methadone Absorption Bioavailability - highly variable % Tmax 1 to 7.5hours 85 90% protein bound 17
18 Methadone Distribution Methadone is highly lipophilic Lipophilicity causes redistribution into fat large.jpg&imgrefurl= Br-1L-O6goxN8zOrduezR2ShQKs=&h=399&w=600&sz=17&hl=en&start=21&zoom=1&tbnid=- KoYcPLae9lo2M:&tbnh=90&tbnw=135&ei=gnoXT8OtGujWiAKd6d3fDw&prev=/search%3Fq%3Ddistribution%2Bof%2Bfat%26um%3D1%26hl%3Den%26sa%3DN%26gbv%3D2%26tbm%3Disch& Methadone Metabolism Duration of action increases with increased dosing T½ of up to hours Analgesic action is shorter than t½ Metabolism is ALWAYS variable 3A4, 1A2, 2D6 Methadone Elimination Methadone is eliminated almost completely in the feces Very long elimination phase 18
19 Methadone Kinetics t½ = 24hr (average) Steady state not achieved until hr Accumulation occurs in 5-10 days Oral Morphine Dose <100 mg 3: mg 5: mg 10:1 Morphine : Methadone ratio Note ratio only represents chronic methadone use mg 12: mg 15:1 >1000 mg 20:1 Methadone Side Effects Less constipation than other opiates Sedation Respiratory depression QT prolongation Ketamine Mechanism of action NMDA receptor antagonist Analgesic Psychomimetic Opioid sparing effect through Attenuation of the occurrence of opioid dependence Reduces opioid withdrawl Side effects Cardiovascular Arrythmia (brady/tachycardia) Hyper/Hypotension Rash Anorexia/nausea/salivation Emergence reactions Vivid dreams Hallucinations/delirium 10 to 20% of patients at anesthetic doses 19
20 Topic Discussion Pharmacist role in pain management Restriction of hydromorphone on formularies Use of Exparel Students who look at these in advance can bring up some topic discussion! Fibromyalgia Epidemiology Affects 2 10% of the general population, in all ages, ethnic groups, and cultures Its gender distribution is up to seven times more common in females than males 15% of patients receive disability funding Fibromyalgia Chronic widespread pain for which no alternative cause can be identified (diagnosis of exclusion) Rheumatologic syndrome characterized by chronic, diffuse musculoskeletal pain and tenderness sleep disturbances fatigue affective dysfunction 20
21 Fibromyalgia Pathophysiology Neuroendocrine: Dysfunction of the hypothalamic-pituitary-adrenal axis Blunted cortisol response Abnormal growth hormone regulation Stage 4 sleep disruption Neurotransmitter: Elevated levels of Tryptophan in CNS but decreased 5HT 3 Elevated levels of substance P in the CSF Elevated levels of nerve growth factor in the CSF Fibromyalgia pathophysiology Neurosensory: Central amplification of pain and/or reduced antinociception Genetic: polymorphisms of genes in the catacholaminergic systems Trauma: 22% of patients get fibromyalgia symptoms after a whiplash accident Fibromyalgia Treatment Goal is NOT resolution of symptoms Significant improvement can be obtained with adequate therapy MANAGEMENT is multimodal Self care Psychological/psychiatric support Physical therapy +/- TENS Pharmacologic treatment 21
22 Pharmacology for Fibromyalgia Low-dose tricyclic antidepressants (amitriptyline) Dual serotonin-norepinephrine reuptake inhibitors Antiepileptic (gabapentin, pregabalin) Selective serotonin reuptake inhibitors Fibromyalgia Treatment in a nutshell Naltrexone Opioid antagonist Best evidence for pain treatment is at low doses reducing pain intensity and improving mood. Low side effect profile. Should never be co-administered with opioids The primary mechanism of low-dose naltrexone is thought to be immune modulation Also has some evidence in hyperalgesia 22
23 Questions 1. Watkins EA, Wollan PC, Melton LJ 3rd, Yawn BP. A population in pain: report from the Olmsted County health study. Pain Med. 2008;9: Blay SL, Andreoli SB, Gastal FL. Chronic painful physical conditions, disturbed sleep and psychiatric morbidity: results from an elderly survey. Ann Clin Psychiatry. 2007;19: Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research Washington, DC. The National Academies Press. 5. Sawyer P, Lillis JP, Bodner EV, Allman RM. Substantial daily pain among nursing home residents. J Am Med Directors Assoc. 2007; Von Korff M, Lin EH, Fenton JJ, Saunders K. Frequency and priority of pain patients health care use. Clin J Pain. 2007;23: Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290: Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers --- United States, MMWR. 2011;60: Melzack R, Casey KL. Sensory, motivational, and central control determinants of pain: A new conceptual model. In: Kenshalo D, ed. The Skin Senses. Springfield, IL: Charles C. Thomas; 1968: Willis WD. The somatosensory system, with emphasis on structures important for pain. Brain Res Rev. 2007;55: Stein C, Clark JD, Oh U, et al. RH. Peripheral mechanisms of pain and 13. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain. 2005;9: Jarvis MF, Boyce-Rustay JM. Neuropathic pain: models and mechanisms. Curr Pharm Des. 2009;15: Portenoy RK. Issues in the management of neuropathic pain. In: Basbaum AI, Besson J-M, eds. Towards a New Pharmacotherapy of Pain. Chichester, UK: John Wiley & Sons, 1991: Truini A, Cruccu G. Pathophysiological mechanisms of neuropathic pain. Neurol Sci May;27 Suppl 2:S Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: Implications for mechanisms of pain. Pain. 2007;131: Dickinson BD, Head CA, Gitlow S, Osbahr A. Maldynia: Pathophysiology and Management of Neuropathic and Maladaptive Pain A Report of the AMA Council on Science and Public Health Pain Med. 2010;11: Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32: Bingel U, Tracey I. Imaging CNS modulation of pain in humans. Physiology (Bethesda). 2008;23: Gamsa A. The role of psychological factors in chronic pain. I. A half century of study. Pain. 1994;57:
24 22. Pain Disorder. In: Frances A, Pincus HA, First MB, et al, eds. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000: Lebovitz A. The psychological assessment of pain in patients with chronic pain. In Wilson PR, Watson PJ, Haythornwaite, Jensen TS, eds. Chronic Pain (Clinical Pain Management, 2nd Edition). London: Hodder and Stoughton Ltd. 2008: Donohoe CD. Evaluation of the Patient in Pain-Targeted History and Physical Examination. In: Waldman SD, Winnie AP, eds. Interventional Pain Management. Philadelphia, PA: WB Saunders; Portenoy RK, Kanner RM. Definition and assessment of pain. In: Portenoy RK, Kanner RM, eds. Pain Management: Theory and Practice. Philadelphia, PA: FA Davis;
Spinal Cord Injury Pain. Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018
Spinal Cord Injury Pain Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018 Objectives At the conclusion of this session, participants should be able to: 1. Understand the difference between nociceptive
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationTreatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am
Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Tim R Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Cleveland Clinic Akron General Center for Family
More informationPrescription Pain Management. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita 1 Narciso Pharm D
Prescription Pain Management University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita 1 Narciso Pharm D 2 Objectives Understand how to preform a pain assessment Know which medications
More informationNeuropathic Pain in Palliative Care
Neuropathic Pain in Palliative Care Neuropathic Pain in Advanced Cancer Affects 40% of patients Multiple concurrent pains are common Often complex pathophysiology with mixed components Nocioceptive Neuropathic
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationPharmacology of Pain Transmission and Modulation
Pharmacology of Pain Transmission and Modulation 2 Jürg Schliessbach and Konrad Maurer Nociceptive Nerve Fibers Pain is transmitted to the central nervous system via thinly myelinated Aδ and unmyelinated
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationReceptors and Neurotransmitters: It Sounds Greek to Me. Agenda. What We Know About Pain 9/7/2012
Receptors and Neurotransmitters: It Sounds Greek to Me Cathy Carlson, PhD, RN Northern Illinois University Agenda We will be going through this lecture on basic pain physiology using analogies, mnemonics,
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationMedications for the Treatment of Neuropathic Pain
Medications for the Treatment of Neuropathic Pain February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation Neuropathic Pain Pain, paresthesias, and sensory
More informationChoose a category. You will be given the answer. You must give the correct question. Click to begin.
Instructions for using this template. Remember this is Jeopardy, so where I have written Answer this is the prompt the students will see, and where I have Question should be the student s response. To
More informationPAIN & ANALGESIA. often accompanied by clinical depression. fibromyalgia, chronic fatigue, etc. COX 1, COX 2, and COX 3 (a variant of COX 1)
Pain - subjective experience associated with detection of tissue damage ( nociception ) acute - serves as a warning chronic - nociception gone bad often accompanied by clinical depression fibromyalgia,
More informationA Pain Management Primer for Pharmacists. Jessica Geiger-Hayes, PharmD, BCPS, CPE Andrea Wetshtein, PharmD, BCPS, CPE
A Pain Management Primer for Pharmacists Jessica Geiger-Hayes, PharmD, BCPS, CPE Andrea Wetshtein, PharmD, BCPS, CPE Objectives Discuss the differences between somatic, visceral, and neuropathic pain Design
More informationPain Management in the
Pain Management in the Elderly Meri Hix, PharmD, CGP, BCPS Associate Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy No conflicts of interest to declare Objectives Discuss
More informationBEYOND OPIOIDS: ADJUNCTS FOR TREATING PAIN
BEYOND OPIOIDS: ADJUNCTS FOR TREATING PAIN Ronald Januchowski, D.O. 2017 Objectives By the end of the presentation, the learner should be able to: Summarize the risks of opiates when used for non-cancer
More information8/28/2012. Disclosure. Accreditation. Neuropathic Pain: Overview and Management. Pharmacists: L01-P
Neuropathic Pain: Overview and Management Shyam Gelot, Pharm.D. Assistant Professor University of South Florida College of Pharmacy September 8, 2013 Disclosure I have nothing to disclose concerning possible
More informationMANAGEMENT OF DIABETIC NEUROPATHY. Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D.
MANAGEMENT OF DIABETIC NEUROPATHY Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D. The Diabetic neuropathy cannot be reversed Not to restore function to damaged nerve Slowly progress no initial
More informationUCSF Pediatric Hospital Medicine Boot Camp Pain Session 6/21/14. Cynthia Kim and Stephen Wilson
UCSF Pediatric Hospital Medicine Boot Camp Pain Session 6/21/14 Cynthia Kim and Stephen Wilson Rules Buzz first and player answers If answer correct, then the player asks teammates if they want to keep
More informationBrian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD
Brian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD 1630 Main Street Suite 215 Chester, MD 410-571-9000 www.4-no-pain.com
More informationI s s u e 1,
I s s u e 1, 2 0 1 4 Guidelines for the Pharmacological Treatment of Peripheral Neuropathic Pain: Expert Panel Recommendations for the Middle East Region EFNS guidelines on the pharmacological treatment
More informationNon-opioid and adjuvant pain management
Non-opioid and adjuvant pain management ALLISON JORDAN, MD, HMDC MEDICAL DIRECTOR OF PALLIATIVE CARE SERVICES CHRISTIAN AND ALTON MEMORIAL HOSPITALS ASSOCIATE MEDICAL DIRECTOR, BJC HOSPICE ASSISTANT PROFESSOR
More informationPain Pathways. Dr Sameer Gupta Consultant in Anaesthesia and Pain Management, NGH
Pain Pathways Dr Sameer Gupta Consultant in Anaesthesia and Pain Management, NGH Objective To give you a simplistic and basic concepts of pain pathways to help understand the complex issue of pain Pain
More informationAcute Pain NETP: SEPTEMBER 2013 COHORT
Acute Pain NETP: SEPTEMBER 2013 COHORT Pain & Suffering an unpleasant sensory & emotional experience associated with actual or potential tissue damage, or described in terms of such damage International
More informationFibromyalgia: Current Trends and Concepts
Fibromyalgia: Current Trends and Concepts Dr. Brian Kahan Fellow American Academy of Physical Medicine and Rehabilitation Diplomat American Academy of Pain Medicine American College of Rheumatology (ACR)
More informationComplex Acute Surgical Pain Management. Thomas Baribeault MSN, CRNA
Complex Acute Surgical Pain Management Thomas Baribeault MSN, CRNA Introduction Anatomy and pathophysiology of acute surgical pain Pharmacology Chronic pain patient Opioid tolerant patient Introduction
More informationDrugs Used In Management Of Pain. Dr. Aliah Alshanwani
Drugs Used In Management Of Pain Dr. Aliah Alshanwani 1 Drugs Used In Management Of Pain A CASE OF OVERDOSE Sigmund Freud, the father of psychoanalysis His cancer of the jaw was causing him increasingly
More informationDiabetic Peripheral Neuropathic Pain: Evaluating Treatment Options
Diabetic Peripheral Neuropathic Pain: Evaluating Treatment Options Ramon L. Cuevas-Trisan, MD Disclosures Speakers Bureau/Honoraria: Allergan, Ipsen 1 Learning Objectives Discuss practical approaches to
More informationOST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO
OST Pharmacology & Therapeutics Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO Disclaimer In the past two years I have received no payment for services from any agency other than government or academic.
More informationOverview of Neuropathic pain
Overview of Neuropathic pain Kongkiat Kulkantrakorn,M.D. Neurology division Thammasat University 1 Contents Overview of pain New concepts and mechanism Treatment options New data in management 2 3 Breaking
More informationAnalgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I. Mr.D.Raju,M.pharm, Lecturer
Analgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I Mr.D.Raju,M.pharm, Lecturer Mechanisms of Pain and Nociception Nociception is the mechanism whereby noxious peripheral stimuli are transmitted to
More informationAction Potentials and Synaptic Transmission. BIO 219 Napa Valley College Dr. Adam Ross
Action Potentials and Synaptic Transmission BIO 219 Napa Valley College Dr. Adam Ross Review of action potentials Nodes of Ranvier Nucleus Dendrites Cell body In saltatory conduction, the nerve impulses
More informationUnderstanding Fibromyalgia
Page 1 Accreditation: Pharmacist 798-000-08-074-L01-P Technicians- 798-000-08-074-L01-T Target Audience: Pharmacists & Technicians CE Credits: 1.0 Credit hour or 0.1 CEU for pharmacists/technicians Expiration
More informationNarcotic Analgesics. Jacqueline Morgan March 22, 2017
Narcotic Analgesics Jacqueline Morgan March 22, 2017 Pain Unpleasant sensory and emotional experience with actual or potential tissue damage Universal, complex, subjective experience Number one reason
More information3/1/2018. Disclosures. Objectives. Clinical advisory board member- Daiichi Sankyo
Adjuvant pain medications in geriatrics Thomas B. Gregory, Pharm.D., BCPS, CPE, FASPE Clinical Pharmacy Specialist Pain Management CoxHealth Springfield, MO Disclosures Clinical advisory board member-
More informationPalliative Care: Treatment at the End of Life
Page 1 Palliative Care: Treatment at the End of Life This webcast has been supported by an educational grant from Purdue Pharma L.P. Mary Lynn McPherson, Pharm.D., BCPS, CDE Professor, University of Maryland
More informationRational Polypharmacy
Rational Polypharmacy Thomas B. Gregory, PharmD, BCPS, CPE, FASPE Disclosures Clinical advisory board: Daiichi Sankyo 1 Introduction Cox Health Ambulatory Pain Clinic Pharmacy Specialist Learning Objectives
More informationCorporate Medical Policy
Corporate Medical Policy Intravenous Anesthetics for the Treatment of Chronic Pain File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intravenous_anesthetics_for_the_treatment_of_chronic_pain
More informationSeizure: the clinical manifestation of an abnormal and excessive excitation and synchronization of a population of cortical
Are There Sharing Mechanisms of Epilepsy, Migraine and Neuropathic Pain? Chin-Wei Huang, MD, PhD Department of Neurology, NCKUH Basic mechanisms underlying seizures and epilepsy Seizure: the clinical manifestation
More informationlocated in the periaqueductal gray matter and dorsolateral fasciculus (Lissauer tract) of the spinal cord, are activated to modulate the transmission
CONTEMPORARY MANAGEMENT OF NEUROPATHIC REVIEW PAIN Contemporary Management of Neuropathic Pain for the Primary Care Physician HSIUPEI CHEN, MD; TIM J. LAMER, MD; RICHARD H. RHO, MD; KENNETH A. MARSHALL,
More informationNeuropathic Pain. Scott Magnuson, MD Pain Management of North Idaho, PLLC
Neuropathic Pain Scott Magnuson, MD Pain Management of North Idaho, PLLC Pain is our friend "An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described
More informationNational Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007
Pregabalin (Lyrica) for fibromyalgia September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lyrica) Reference Number: HIM.PA.64 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationDisclosures. Objectives 9/8/2015
The Aftermath of the Decade of Pain: Alternatives to Opioids in Chronic Pain Management Julie Cunningham, PharmD, BCPP Disclosures No relevant financial disclosures I will discuss off-label uses of antiepileptics,
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 03 Nov 2018 09:24:50 GMT) CTRI Number Last Modified On 10/06/2013 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationRefractory Central Neurogenic Pain in Spinal Cord Injury. Case Presentation
Refractory Central Neurogenic Pain in Spinal Cord Injury Case Presentation Edwin B. George, MD, PhD Wayne State University John D. Dingell VAMC 2012 Disclosures This continuing education activity is managed
More informationPOST OPERATIVE PAIN MANAGEMENT: PAIN AND COMPLICATIONS
POST OPERATIVE PAIN MANAGEMENT: PAIN AND COMPLICATIONS November 9, 2018 Aimee LaMere, CNP Molly McNaughton, CNP Leslie Weide, MSW, LICSW, ACM Disclosures: Conflict of interest statement: We certify that,
More informationAcute Pain Management
Idaho Society of Health-System Pharmacists Acute Pain Management Alex Ham, PharmD and Monica McLain, PharmD Saint Alphonsus Regional Medical Center PGY1 Residents September 28, 2018 Disclosures Neither
More informationInpatient Management of Trauma Related Pain
Inpatient Management of Trauma Related Pain STOMP Summit September 9, 2016 Ann O Rourke, MD, MPH University of Wisconsin Department of Surgery 1 Our patient Small SDH Intubated Hemopneumothorax with multiple
More informationSteven Richeimer, M.D.
Steven Richeimer, M.D. Associate Professor of Anesthesiology & Psychiatry Chief, Division of Pain Medicine Keck School of Medicine, USC Los Angeles, CA 323-442-6202 www.helpforpain.com Pain Light touch
More informationManagement of Pain. Agenda: Definitions Pathophysiology Analgesics
C. Brian Warriner, MD, FRCPC Professor and Past Chair UBC Department of Anesthesiology, Pharmacology and Therapeutics brian.warriner@vch.ca Agenda: Definitions Pathophysiology Analgesics Gases(N 2 O) Opiates
More informationPathophysiology of Pain. Ramon Go MD Assistant Professor Anesthesiology and Pain medicine NYP-CUMC
Pathophysiology of Pain Ramon Go MD Assistant Professor Anesthesiology and Pain medicine NYP-CUMC Learning Objectives Anatomic pathway of nociception Discuss the multiple target sites of pharmacological
More informationChronic Pain Overview. Mark S. Wallace, M.D. Professor of Clinical Anesthesiology University of California, San Diego
Chronic Pain Overview Mark S. Wallace, M.D. Professor of Clinical Anesthesiology University of California, San Diego Physiology of Pain Perception CORE Transduction Transmission Modulation Perception Interpretation
More informationPain Management in a Geriatric Population. Alan Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy of Florida
Pain Management in a Geriatric Population Alan Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy of Florida Objectives Review definitions and types of pain Discuss purpose and value of pain
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More informationLYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS
Volume 20, Issue 7 April 2005 LYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS Tanja Lepir, Pharm.D. Candidate Nervous system dysfunction leading to neuropathic pain can occur from many causes: infection,
More informationSan Francisco Chronicle, June 2001
PAIN San Francisco Chronicle, June 2001 CONGENITAL INSENSITIVITY TO PAIN PAIN IS A SUBJECTIVE EXPERIENCE: It is not a stimulus MAJOR FEATURES OF THE PAIN EXPERIENCE: Sensory discriminative Affective (emotional)
More informationReview Normal Pain Anatomy and Physiology Pathological Pain Pathways? Targeted Treatments Future Developments 9/26/2011
Jeremy A. Adler, MS, PA C Pacific Pain Medicine Consultants Encinitas, CA Consultant Pfizer Endo Pharmaceuticals Azur Pharma Janssen Pharmaceuticals St. Jude Medical As part of this presentation, off label
More informationCANNABIS AND PAIN. Debra Kimless, M.D. Medical Director, ForwardGro MAOP Annual Meeting September 14, 2018
CANNABIS AND PAIN Debra Kimless, M.D. Medical Director, ForwardGro MAOP Annual Meeting September 14, 2018 FDA APPROVAL: PREGABALIN, DULOXETINE, MILNACIPRAN FOR FIBROMYALGIA PREGABALIN, DULOXETINE FOR
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More informationMANAGEMENT OF VISCERAL PAIN
MANAGEMENT OF VISCERAL PAIN William D. Chey, MD, FACG Professor of Medicine University of Michigan 52 year old female with abdominal pain 5 year history of persistent right sided burning/sharp abdominal
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More information211MDS Pain theories
211MDS Pain theories Definition In 1986, the International Association for the Study of Pain (IASP) defined pain as a sensory and emotional experience associated with real or potential injuries, or described
More informationPain Signaling Neuropathic Pain Distinctly different from nociceptive pain Sustained by abnormal processing of sensory input by the peripheral or cent
Objectives Pharmacologic Management of Neuropathic Pain Joseph R. Ineck, Pharm.D.,., CPE Pharmacist: St. Luke s Health System At the conclusion of this presentation, pharmacists will be able to: 1. Differentiate
More informationManagement of Pain related to Spinal Cord Lesion
Management of Pain related to Spinal Cord Lesion A Neurologist s Perspective Vincent Mok, MD Associate Professor Division of Neurology Department of Medicine and Therapeutics The Chinese University of
More informationMitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly
Mitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly Mary Lynn McPherson, PharmD, MDE, MA, BCPS, CPE Professor and Executive Director, Advanced Post-Graduate
More informationThe Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI
More informationPain. Pain. Pain: One definition. Pain: One definition. Pain: One definition. Pain: One definition. Psyc 2906: Sensation--Introduction 9/27/2006
Pain Pain Pain: One Definition Classic Paths A new Theory Pain and Drugs According to the international Association for the Study (Merskey & Bogduk, 1994), Pain is an unpleasant sensory and emotional experience
More informationAcute Pain Management in the Hospital Setting. Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX
Acute Pain Management in the Hospital Setting Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX 2 What is Pain? An unpleasant sensory and emotional experience associated
More informationNon-Opioid Drugs to Treat Neuropathic Pain. March 2018
Non-Opioid Drugs to Treat Neuropathic Pain Final Report March 2018 This report is intended only for state employees in states participating in the Drug Effectiveness Review Project (DERP). Do not distribute
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationGoals for sedation during mechanical ventilation
New Uses of Old Medications Gina Riggi, PharmD, BCCCP, BCPS Clinical Pharmacist Trauma ICU Jackson Memorial Hospital Disclosure I do not have anything to disclose Objectives Describe the use of ketamine
More informationThe Nervous System. Anatomy of a Neuron
The Nervous System Chapter 38.1-38.5 Anatomy of a Neuron I. Dendrites II. Cell Body III. Axon Synaptic terminal 1 Neuron Connections dendrites cell body terminal cell body cell body terminals dendrites
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Anxiolytic and Hypnotic Drugs Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 OTHER ANXIOLYTIC AGENTS/ A. Antidepressants Many antidepressants are effective in the treatment
More informationChapter 16. Sense of Pain
Chapter 16 Sense of Pain Pain Discomfort caused by tissue injury or noxious stimulation, and typically leading to evasive action important /// helps to protect us lost of pain in diabetes mellitus = diabetic
More informationKaram Darwish. Dr. Munir. Munir Gharaibeh
7 Karam Darwish Dr. Munir Munir Gharaibeh Opioid Analgesics Pain is an important symptom as it is usually the symptom that brings the patient to the hospital, and an Analgesic is a drug used to relieve
More informationAgonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone
Opioid Definition All drugs, natural or synthetic, that bind to opiate receptors Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone Opioid agonists increase pain threshold
More informationThe clinical landscape of painful diabetic neuropathy therapy: perspectives for clinicians from clinical practice guidelines
The clinical landscape of painful diabetic neuropathy therapy: perspectives for clinicians from clinical practice guidelines Clin. Invest. (2012) 2(5), 483 489 Painful diabetic neuropathy (PDN) is highly
More informationPractical Pain Management Leah Centanni, MSN, FNP-C, Asst. Clinical Professor CANP Conference March 22, 2014
Practical Pain Management Leah Centanni, MSN, FNP-C, Asst. Clinical Professor CANP Conference March 22, 2014 Overview Types of Pain Physical Examination of Pain Pharmacologic Approach in Pain Management
More informationCHAMP: Bedside Teaching TREATING PAIN. Stacie Levine MD. What is the approach to treating pain in the aging adult patient?
CHAMP: Bedside Teaching TREATING PAIN Stacie Levine MD Teaching Trigger: An older adult patient is identified as having pain. Clinical Question: What is the approach to treating pain in the aging adult
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationAcute Pain Management in the Opioid Tolerant Patient. Objectives. Opioids. The participant will be able to define opioid tolerance
Acute Pain Management in the Opioid Tolerant Patient Kathleen M. Colfer, MSN, RN-BC Clinical Nurse Specialist Acute Pain Management Service Department of Anesthesiology Thomas Jefferson University Hospital
More informationThe Nervous System. Chapter 4. Neuron 3/9/ Components of the Nervous System
Chapter 4 The Nervous System 1. Components of the Nervous System a. Nerve cells (neurons) Analyze and transmit information Over 100 billion neurons in system Four defined regions Cell body Dendrites Axon
More informationPeripheral neuropathy (PN)
Peripheral neuropathy (PN) damage or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of health, depending on the type of nerve affected o chronic:
More informationAchieving Optimal Therapeutic Outcomes in Pain Management from a Pharmacist's Perspective
Achieving Optimal Therapeutic Outcomes in Pain Management from a Pharmacist s Perspective Chris Herndon, PharmD, BCPS, CPE Assistant Professor Southern Illinois University Edwardsville Clinical Pharmacy
More informationWhat it Takes to be a Pain
What it Takes to be a Pain Pain Pathways and the Neurophysiology of pain Dennis S. Pacl, MD, FACP, FAChPM Austin Palliative Care/ Hospice Austin A Definition of Pain complex constellation of unpleasant
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationPain Management in the Elderly. Martha Watson, MS, APRN, GCNS Christie Bowser, RN-BC, RN
Pain Management in the Elderly Martha Watson, MS, APRN, GCNS Christie Bowser, RN-BC, RN Objectives So How Much Do You Really Know? www.geriatricpain.org Geriatric Pain Knowledge Assessment The Geriatric
More informationPAIN IS A SUBJECTIVE EXPERIENCE: It is not a stimulus. MAJOR FEATURES OF THE PAIN EXPERIENCE: Sensory discriminative Affective (emotional) Cognitive
PAIN PAIN IS A SUBJECTIVE EXPERIENCE: It is not a stimulus MAJOR FEATURES OF THE PAIN EXPERIENCE: Sensory discriminative Affective (emotional) Cognitive MEASUREMENT OF PAIN: A BIG PROBLEM Worst pain ever
More informationBasics of Pharmacology
Basics of Pharmacology Pekka Rauhala Transmed 2013 What is pharmacology? Pharmacology may be defined as the study of the effects of drugs on the function of living systems Pharmacodynamics The mechanism(s)
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress REDUCING THE PAIN FACTOR AN UPDATE ON PERI-OPERATIVE ANALGESIA Sandra Forysth, BVSc DipACVA Institute of Veterinary,
More informationPain CONCERN. Medicines for long-term pain. Antidepressants
Pain CONCERN Medicines for long-term pain Antidepressants Many people living with long-term pain (also known as chronic or persistent pain) are worried about using medicines like antidepressants. They
More informationADJUVANT PAIN MANAGEMENT
ADJUVANT PAIN MANAGEMENT Bruce H. Chamberlain, MD FACP FAAHPM Palliative Consulting Orem, UT AAHPM Intensive Board Review Course Using Adjuvant Treatments for Chronic Pain Bruce H. Chamberlain, MD FACP
More informationDisclosures. Management of Chronic, Non- Terminal Pain. Learning Objectives. Outline. Drug Schedules. Applicable State Laws
Disclosures Management of Chronic, Non- Terminal Pain No financial disclosures or conflicts of interest to report Michael A. Smith, PharmD, BCPS Clinical Assistant Professor, University of Michigan College
More informationAmber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center
Pharmacologic Management of Pain Amber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center Objectives Identify types of
More informationPharmacology of Opioid Analgesics
Pharmacology of Opioid Analgesics Harvey Berman, PhD, MPH Department of Pharmacology and Toxicology hberman@buffalo.edu (716) 829-2658 1 01-OPIOID_ANALGESIA_2018 - November 17, 2018 NO SIGNIFICANT FINANCIAL,
More informationSomatosensory Physiology (Pain And Temperature) Richard M. Costanzo, Ph.D.
Somatosensory Physiology (Pain And Temperature) Richard M. Costanzo, Ph.D. OBJECTIVES After studying the material of this lecture the student should be familiar with: 1. The relationship between nociception
More informationPain. November 1, 2006 Dr. Jana Pilkey MD, FRCP(C) Internal Medicine, Palliative Medicine
Pain November 1, 2006 Dr. Jana Pilkey MD, FRCP(C) Internal Medicine, Palliative Medicine Objectives To be able to define pain To be able to evaluate pain To be able to classify types of pain To learn appropriate
More informationUnderstanding and Treating Post- Herpetic Neuralgia (PHN)
Understanding and Treating Post- Herpetic Neuralgia (PHN) Mary Lynn McPherson, Pharm.D., BCPS Professor University of Maryland School of Pharmacy mmcphers@rx.umaryland.edu This program has been supported
More information